Membrane stabilizer: citicoline
- PMID: 12365823
- DOI: 10.1185/030079902125000679
Membrane stabilizer: citicoline
Abstract
Brain ischaemia leads to a cascade of biochemical events, many of which ultimately cause cell membrane injury. Therefore, measures aimed at protecting neuronal membranes could be useful treatment strategies following stroke. Citicoline (cytidine-5-diphosphocholine; CDP-choline) is a naturally occurring nucleotide derivative that may reduce central nervous system (CNS) ischaemic injury by stabilizing cell membranes and reducing free radical generation. Several animal models of ischaemic stroke or hypoxia have shown beneficial effects of citicoline treatment. Randomized clinical stroke treatment trials performed outside of the United States (US) have shown promising results but several recent US trials have failed to support the use of citicoline following middle cerebral artery (MCA) stroke. It remains possible that more specific subgroups of patients may benefit from this well tolerated therapy, but these subgroups have yet to be determined. In addition, there remains the possibility that efficacy may be seen when citicoline is administered in combination with other neuroprotectants with complementary mechanisms of action.
Similar articles
-
Efficacy of citicoline as an acute stroke treatment.Expert Opin Pharmacother. 2009 Apr;10(5):839-46. doi: 10.1517/17460440902835475. Expert Opin Pharmacother. 2009. PMID: 19351232
-
CDP-choline: pharmacological and clinical review.Methods Find Exp Clin Pharmacol. 1995 Oct;17 Suppl B:1-54. Methods Find Exp Clin Pharmacol. 1995. PMID: 8709678 Review.
-
Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature.Altern Med Rev. 2004 Mar;9(1):17-31. Altern Med Rev. 2004. PMID: 15005642 Review.
-
Citicoline: pharmacological and clinical review, 2006 update.Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56. Methods Find Exp Clin Pharmacol. 2006. PMID: 17171187 Review.
-
A randomized efficacy trial of citicoline in patients with acute ischemic stroke.Stroke. 1999 Dec;30(12):2592-7. doi: 10.1161/01.str.30.12.2592. Stroke. 1999. PMID: 10582983 Clinical Trial.
Cited by
-
Citicoline: pharmacological and clinical review, 2022 update.Rev Neurol. 2022 Nov 30;75(s05):S1-S89. doi: 10.33588/rn.75s05.2022311. Rev Neurol. 2022. PMID: 36544369 Free PMC article. Review. English, Spanish.
-
Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.Diagnostics (Basel). 2023 Aug 18;13(16):2703. doi: 10.3390/diagnostics13162703. Diagnostics (Basel). 2023. PMID: 37627961 Free PMC article.
-
Protective Effects of Citicoline and Benfotiamine Each Alone and in Combination on Streptozotocin-induced Memory Impairment in Mice.Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):81-92. doi: 10.9758/cpn.2020.18.1.81. Clin Psychopharmacol Neurosci. 2020. PMID: 31958909 Free PMC article.
-
Citicoline (Cognizin) in the treatment of cognitive impairment.Clin Interv Aging. 2006;1(3):247-51. doi: 10.2147/ciia.2006.1.3.247. Clin Interv Aging. 2006. PMID: 18046877 Free PMC article. Review.
-
Treating the acute stroke patient as an emergency: current practices and future opportunities.Int J Clin Pract. 2006 Apr;60(4):399-407. doi: 10.1111/j.1368-5031.2006.00873.x. Int J Clin Pract. 2006. PMID: 16620351 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources